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ABSTRACT
The nucleoporin 98 gene (NUP98) has been reported to be fused to 13
partner genes in hematological malignancies with 11p15 translocations.
Twelve of them have been identified in patients with myeloid neoplasias
and only 1, RAP1GDS1 (4q21), is fused with NUP98 in five patients with
T-cell acute lymphoblastic leukemia (T-ALL). Three of these patients
coexpressed T and myeloid markers, suggesting the specific association of
t(4;11)(q21;p15) with a subset of T-ALL originating from an early pro-
genitor, which has the potential to express mature T-cell antigens as well
as myeloid markers. We describe here a new NUP98 partner involved in
a t(10;11)(q25;p15) in a patient with acute biphenotypic leukemia, show-
ing coexpression of mature T and myeloid markers. The gene involved,
located in 10q25, was identified as ADD3 using 3-RACE. ADD3 codes for
the ubiquitous expressed subunit  of the adducin protein, and it seems to
play an important role in the skeletal organization of the cell membrane.
Both NUP98-ADD3 and ADD3-NUP98 fusion transcripts are expressed in
the patient. This is the second partner of NUP98 described in T-ALL.
Adducin shares with the product of RAP1GDS1, and with all of the
nonhomeobox NUP98 partners, the presence of a region with significant
probability of adopting a coiled-coil conformation. This region is always
retained in the fusion transcript with the NH2 terminus FG repeats of
NUP98, suggesting an important role in the mechanism of leukemogenesis.
INTRODUCTION
The NUP98 protein is a Mr 98,000 component of the NPC,3 which
regulates nucleocytoplasmic transport of RNA and proteins, and re-
sides asymmetrically on the nucleoplasmic side of the NPC. The
protein consists of 37 FG repeats located in the NH2 terminus that
comprise the first and third functional domains that are docking sites
for cellular transport receptors. The second and fourth domains con-
tain a Gle2p binding-like motif and a ribonucleoprotein-binding motif,
respectively. The NUP98 COOH terminus seems to function as a
nuclear localization signal (1, 2). The NUP98 gene, located on
11p15.4, was identified at the site of a t(7;11)(p15;p15.4) chromo-
somal translocation. The partner in this translocation was the class-1
homeobox gene HOXA9 (3, 4). To date, NUP98 has been shown to be
fused to another 11 partners in myeloid neoplasms, the class-1 ho-
meobox genes HOXD13 (2q31; Ref. 5), HOXD11 (2q31; Ref. 2),
HOXA13 (7p15; Refs. 6, 7), HOXA11 (7p15; Ref. 7), and HOXC11
(12q13; Ref. 8); the class-2 homeobox gene PMX1 (1q23; Ref. 9); and
to 5 nonhomeobox genes: NSD1 (5q35; Ref. 10), NSD3 (8p11; Ref.
11), LEDGF (9p22; Ref. 12), DDX10 (11q22; Ref. 13), and TOP1
(20q11; Ref. 14). All these genes have been characterized in patients
with de novo or therapy-related acute myeloid leukemia or myelodys-
plastic syndrome. In lymphoid malignancies, a newly established
reciprocal translocation t(4;11)(q21;p15), which resulted in a NUP98-
RAP1GDS1 fusion, has been described in five patients with T-ALL
(15). Three of these patients coexpressed mature T and myeloid
markers, suggesting the specific association of t(4;11)(q21;p15) with
a subset of T-ALL originating from an early progenitor, which has the
potential to express mature T-cell antigens and myeloid markers (15,
16).
The NUP98-HOX fusion transcripts join the NUP98 NH2-terminal FG
repeat motif with the 3 region of the partner genes. The fusion always
conserves the homeodomain shared by the HOX genes, suggesting that
the homeodomain expression is up-regulated. The resulting fusion protein
could act as an oncogenic transcription factor, being critical for leuke-
mogenesis (1, 9). The non-HOX partners of NUP98, including
RAP1GDS1, have been reported to have regions with significant proba-
bility of adopting a coiled-coil conformation, which would result in the
formation of amphipathic  helices. In all cases, the predicted coiled-coil
domains are retained in the chimeric proteins, fused to the FG repeat-rich
NH2 terminus of NUP98. These FG repeats have strong transcriptional
transactivation potential through direct interaction with CBP/p300. The
oligomerization via the coiled-coil domain may activate the oncogenic
potential of the fusion gene and facilitate interactions with other tran-
scription factors or cofactors (17).
We report here a case of T-ALL coexpressing myeloid markers,
with a new t(10;11)(q25;p15) involving NUP98 and a new partner,
ADD3. To date, this is the second NUP98 partner associated with this
subset of T-ALL.
PATIENTS AND METHODS
Case Report. A 23-year-old Caucasian male was admitted with adenopa-
thies lasting for 4 months, moderate splenomegaly, and the following blood
hematological findings: WBC, 4.8  109/liter with 12% blasts; hemoglobin,
13.9 g/dl; and platelets, 227  109/liter. BM aspirate showed 68% blast cells.
Two different morphological populations were detected by flow cytometry
analysis. The minor population was positive for immature markers (CD34,
CD45 weak), myeloid markers (CD13, CD11b weak, CD33, HLA-DR,
cMPO), and T lineage markers (cCD3 and CD7) with absence of B lineage
markers. This population with biphenotypic characteristics (T/myeloid) repre-
sents 31% of the total. The second population of blast cells (37%) expressed
CD34, CD45, and TdT and showed T markers: cCD3, CD7, and CD5, with
absence of B lineage markers or myeloid markers with exception of CD33 and
CD11b. The patient was diagnosed of biphenotypic acute leukemia myeloid/T.
Complete hematological and cytogenetic remission was obtained after induc-
tion regimen 7/3/3 (Ara-C, Idarubin,VP-16). Postremission therapy was made
with two courses of chemotherapy (Ida-Ara-C; Mitoxantrone-Ara-C) followed
by autologous transplantation. The patient continues in complete remission (8
months) without relapsing. Because of the bad prognosis and the absence of
related HLA-identical donors, a search of possible unrelated donors has been
started. Samples were obtained from the patient with informed consent.
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Conventional and Molecular Cytogenetics. Cytogenetic studies were
done on unstimulated short-term BM cultures. G-banded analysis showed a
sole abnormal clone 46,XY,add (11)(p15) in 27 of 35 metaphases. The karyo-
type was described according to the International System for Human Cytoge-
netic Nomenclature (18). FISH studies were performed using two BAC clones:
RPCI-11 348A20, which covers exons 1–26 of the NUP98 gene; and RPCI-11
555F1, located in a region 500 Kb telomeric to NUP98, labeled with Spectrum
Orange and Spectrum Green, (Vysis, Downers Grove, IL) respectively. The
ADD3 gene was studied using BAC RPCI-11 252O7, which covers the whole
gene, labeled with Spectrum Green. Whole chromosome painting was per-
formed using the STAR*FISH human whole chromosome-specific probes
(Cambio, Cambridge, United Kingdom), with probes for chromosome 10 and
11 labeled with FITC and Cy3, respectively. FISH analysis was performed on
BM metaphases as described previously (19). The SKY probe mixture and
hybridization reagents were obtained from Applied Spectral Imaging (Migdal
Ha-Emck, Israel). Slides for spectral karyotyping were hybridized with the
probe mixture as described previously (20).
Nucleid Acid Isolation. Total RNA was extracted using the RNeasy Mini
Kit (Qiagen, Hilden, Germany) from frozen cell pellets of leukemic cells. DNA
from BAC clones was extracted using Qiaprep Spin Miniprep kit (Qiagen).
3-RACE. 3-RACE was performed with the GeneRacer Kit (Invitrogen
Life Technologies, Inc., Paisley, United Kingdom). Briefly, first strand cDNA
was reverse transcribed from 1 g of total RNA using SuperScript II RNase
H RT (Invitrogen Life Technologies, Inc.) and the GeneRacer Oligo dT
Primer; 1 l of the first strand cDNA was then amplified using a NUP98
gene-specific forward primer (NUP98-1) and the GeneRacer 3 Primer. A
nested PCR reaction was performed using the GeneRacer 3 Nested Primer as
the reverse primer and NUP98-2 (internal to NUP98-1) as the forward primer.
In both reactions, after initial denaturation at 94°C for 10 min, 35 cycles at
94°C for 1 min, at 60°C for 1 min, and at 72°C for 1 min were used, followed
by a final elongation at 72°C for 10 min. All primer sequences are shown in
Table 1.
RT-PCR. One g of total RNA from the BM cells of the patient and from
a healthy donor were used for cDNA synthesis using SuperScript II RNase H
RT (Invitrogen Life Technologies, Inc.) with random hexamers. RT-PCR
reactions were carried out with AmpliTaq GoldDNA Polymerase (Applied
Biosystems, Foster City, CA), with the same conditions described above. To
confirm the presence of the NUP98-ADD3 fusion product, RT-PCR was
performed with sense NUP98-1 and antisense ADD3-1 primers (Table 1). A
seminested PCR of the first product was done using sense NUP98-2 and
ADD3-1 primers (Table 1) in the same conditions. Similarly, RT-PCR was
performed to amplify the reciprocal ADD3-NUP98 fusion transcript using
sense ADD3-2 and antisense NUP98-3 primers (Table 1).
DNA Cloning and Sequencing. PCR products from the 3-RACE and
RT-PCR experiments were subcloned using the Topo TA Cloning Kit for
Sequencing (Invitrogen Life Technologies, Inc.). Sixty-eight colonies with
recombinant plasmids containing the PCR products were screened by digestion
with EcoRI (Amersham Biosciences, Buckinghamshire, United Kingdom).
Candidate plasmid clones were sequenced with ABI-PRISM D-Rhodamine
Terminator Cycle Sequencing Kit (Applied Biosystems) in an ABI PRISM 377
DNA Sequencer (Applied Biosystems).
RESULTS AND DISCUSSION
Cytogenetic analysis showed the presence of a sole clone with add
(11)(p15) in 27 of 35 cells in a patient with T-ALL coexpressing
myeloid markers. FISH analysis with BAC RPCI-11 348A20 showed
a split signal, indicating that NUP98 was disrupted as a result of a
cryptic translocation not detected at the G-band level (Fig. 1). To
identify the partner gene, we performed a 3-RACE experiment on
reverse-transcribed RNA isolated from BM of the patient. The 3-
RACE PCR product consisted of a 358-bp sequence fused to exon 10
of NUP98. BLAST search showed that the 358 bp perfectly matched
the gene ADD3 transcript variant 1, which encodes for the subunit 
of the adducin protein. The resultant in-frame chimeric mRNA-joined
nucleotide 1332 of NUP98 to nucleotide 1764 of the gene-encoding
adducin , resulting in the fusion of exon 10 of NUP98 to exon 13 of
ADD3 transcript variant 1. ADD3 transcript variant 1 differs from
variant 2 in the presence of the 96-bp exon 13.
RT-PCR was performed using primers flanking the NUP98-ADD3
junction, and two products of 403 and 307 bp were obtained (Fig. 2).
Sequence analysis of the RT-PCR products confirmed that NUP98
and ADD3 were fused in-frame in both chimeric products. The 403-bp
Fig. 1. G banding and FISH analysis of a patient
with t(10;11)(q25;p15). A, partial G band. Arrows
indicate breakpoints of rearranged chromosomes.
B, FISH analysis with the RPCI-11 348A20 probe
(red), which covers the NUP98 gene, labels normal
chromosome 11, der(11) and der(10). RPCI-11
555F1 (green), located 500 Kb telomeric to
NUP98, labels normal chromosome 11 and der(10).
C, FISH analysis with RPCI-11 252O7 (green),
which covers ADD3, labels normal chromosome
10, der(10) and der(11), and RPCI-11 348A20
(red) labels normal chromosome 11, der(11) and
der(10).
Table 1 Oligonucleotide primer sequences
Primer Oligonucleotide sequence (5-3) Gene Nucleotidesa
NUP98-1 TAAACCAGCACCTGGGACTCTTGGAAC NUP98 1391–1417
NUP98-2 TGGGGCCCCTGGATTTAATACTACGA NUP98 1520–1545
NUP98-3 CTGGGCTGCTGGATTTGTTG NUP98 1748–1729
ADD3-1 GCGGAATTTCTTCTTTTTCTTGGATG ADD3 2101–2076
ADD3-2 GCCCACCAGCTCCTCCTAAC ADD3 1668–1687
a Nucleotide coordinates refer to GenBank accession nos. NM-016320.2 (NUP98) and
NM-016824.1 (ADD3).
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band showed a fusion between exon 10 of NUP98 and exon 13 of
ADD3 transcript variant 1. The 307-bp band showed a fusion between
exon 10 of NUP98 and ADD3 transcript variant 2, lacking the 96-bp
exon 13. The fact that both ADD3 variants were rearranged with
NUP98 suggests that the genomic breakpoint on ADD3 is located
upstream of the region of alternative splicing that leads to the expres-
sion of both of them. The breakpoint in NUP98 was located between
exons 10 and 11 in both transcripts. The reciprocal transcript was also
detected by RT-PCR but with a lower expression, resulting in the
fusion of exon 12 of ADD3 to exon 11 of NUP98.
NUP98-ADD3 transcript variant 1, NUP98-ADD3 transcript var-
iant 2, and the reciprocal ADD3-NUP98 fusion transcript are
predicted to encode proteins of 598, 566, and 1908 amino acids,
respectively. FISH analysis using the BAC RPCI11-252O7, which
covers the ADD3 gene, showed a split signal in both der(10) and
der(11) chromosomes (Fig. 1), confirming the rearrangement. The
chromosome painting probes also confirmed the translocation be-
tween chromosomes 10 and 11. SKY showed that the t(10;11) was
the only cytogenetic aberration in the karyotype (data not shown).
This is the first time the t(10;11)(q25;p15) has been reported.
Rearrangements at 10q25 are rare, probably because it is a very
telomeric band, and it is difficult to identify chromosomal aberra-
tions by G banding in this region (Fig. 1A).
The ADD3 gene codes for the  subunit of the adducin protein.
Adducins are a family of skeletal proteins of the cell membrane,
where they promote the binding of spectrin to actin regulated by
calcium-calmodulin. They are encoded by 3 genes:  (ADD1);
 (ADD2); and  (ADD3; Ref. 21), located in chromosomes 4p16.3,
2p14-p13, and 10q24.2-q24.3, respectively. These subunits share a
similar structure with a protease-resistant NH2-terminal region and a
protease-sensitive hydrophilic COOH-terminal region, the most vari-
able, which contains most of the phosphorylation sites and the binding
site for calmodulin (22). They form heterodimers composed of - or
- subunits.  and  adducins show ubiquitous expression in contrast
to the restricted expression of  adducin, which appears at high levels
only in brain and hematopoietic tissues (BM in humans and spleen in
mice). ADD3 is highly conserved, showing a 86% of homology with
the mouse Add3 (23), suggesting the important function of this protein
in the skeletal organization of the cell membrane (24). Adducin has
been studied in platelets, where its regulation by protein kinase C, and
calpain may play a role in platelet aggregation (25).
To date, NUP98 has been reported to be fused to 12 partner genes
in myeloid neoplasias and to only 1, RAP1GSD1, in five patients with
T-ALL. Therefore, ADD3 is the second partner of NUP98 found in
lymphoid neoplasms and, to our knowledge, it is the first time this
gene has been found involved in human leukemia. Six breakpoints on
NUP98 have been previously described located between exons 7 and
13 (Fig. 3). In the translocation described here, the breakpoint was
located between exons 10 and 11 of NUP98, the same as reported in
the literature for patients involving 10 of the partners, including the
RAP1GDS1 (2–10, 13, 15, 16, 26–30). Interestingly, three of five
T-ALL patients reported to have the NUP98-RAP1GDS1 rearrange-
ment and a biphenotypic leukemia coexpressing T and myeloid mark-
ers had the same breakpoint in NUP98 we detected in our patient.
The NUP98-ADD3 fusion transcript fuses the NH2-terminal FG
repeat motif of NUP98 with the COOH-terminal phosphorylation sites
and the calmodulin binding region of ADD3. In all of the NUP98
translocations reported, the chimeric transcripts expressed consist of
the 5 portion of NUP98 fused-in-frame to the 3 portion of the partner
gene. The FG repeats in the NH2 terminus are always retained,
suggesting that these repeats have an important function in the leu-
kemic transformation. In the NUP98 rearrangements involving the
HOX family, the 3 region of these genes are retained in the fusion,
conserving the homeodomain. This family of genes play a important
role in the normal and malignant hematopoeitic development. The
translocation with NUP98 results in the formation of a chimeric
protein that could act as an oncogenic transcription factor critical for
leukemogenesis (1, 9). The oncogenic mechanism of the transloca-
tions involving non-HOX genes seems to be different because these
proteins are not known to have direct DNA binding properties nor are
they implicated in hematopoyesis development. However, all of the
proteins coded by the non-HOX fusion partners of NUP98 described
to date have regions with significant probability of adopting a coiled-
coil conformation. These domains are characterized by sequence
patterns known as heptad repeats, which result in the formation of
amphipathic  helices. In all cases, the predicted coiled-coil domains
are retained in the fusion protein, leading to a chimeric protein
containing an amino acid sequence with coiled-coil forming potential
fused to the FG repeat-rich NH2 terminus of NUP98. These FG
repeats have strong transcriptional transactivation potential through
direct interaction with CBP/p300 (1). The oligomerization via the
coiled-coil domain may activate the oncogenic potential of the fusion
gene and facilitate the interaction with other transcription factors or
cofactors (17). The analysis with the COILS 2.1 program (17) showed
that the ADD3 protein, as other nonhomeobox proteins involved in
NUP98 rearrangements, is predicted to form a coiled-coil motif at
His556-Asp586 (P  1.0). The self-optimized prediction method
secondary structure prediction program showed that this putative
coiled-coil sequence of the ADD3 protein was predicted to form
-helices as has been shown in smgGDS, the protein encoded by
RAP1GDS1. We have found no structural or functional relationship
between ADD3 and smgGDS other than both proteins are predicted to
form a coiled-coil motif.
Two observations suggest the relationship of this motif with the
cellular transformation. First, the oligomerization via the coiled-coil
domains has been shown to activate the oncogenic potential of RARa
and acute myeloid leukemia 1 genes in rearrangements with fusion
Fig. 2. Detection of the NUP98-ADD3 fusion in the patient. A, seminested RT-PCR
showing amplification of both fusion products in BM of the patient (Lane 1) but not in
normal BM (Lane 2) or normal peripheral blood (Lane 3). M: 1 Kb plus. Lane 4: negative
control. B, schematic representation of the breakpoint (arrow) and the result of the fusion
transcript. NUP98 exon 10 sequence (bold) is followed by ADD3 exon 13 (italics)
transcript variant 1 and by ADD3 exon 14 (italics) transcript variant 2.
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partners that have coiled-coil conformation as PML, PLZF, NPM, and
ETO. Moreover, another component of the NPC, NUP214/CAN, has
been reported to be fused with two proteins that also have a region
with high coiled-coil forming potential, SET and DEK. In both
chimeric transcripts, the multiple FG repeat-rich docking sites of
NUP214/CAN are retained. This also suggests the importance of the
NUP98 FG repeats in leukemogenesis (17).
In conclusion, ADD3 has been reported for the first time as a
translocation partner of NUP98 in acute T-lymphoblastic leukemia
with myeloid markers. To our knowledge, the ADD3 gene has never
been implicated in hematological malignancies. This is the second
NUP98 partner identified in a lymphoid context. ADD3 shares with
the other partner gene previously described, RAP1GDS1, the diagno-
sis of the patient, T-ALL that coexpresses myeloid markers, and the
location of the breakpoint between exons 10 and 11 of NUP98. Both
genes also code for a protein that is predicted to form a coiled-coil
motif. This fact also supports the association of this new NUP98
partner with a subset of T-ALL originated for an early progenitor that
coexpress mature T and myeloid markers. Functional analysis of the
two chimeric transcripts will provide new insights into their specific
role in leukemogenesis.
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